{
 "canonical_id": "sf-19930430-0318",
 "canonical_url": "https://lovspor.no/forskrift/forskrift-om-hva-som-er-dopingmidler/",
 "language": "no",
 "links": {
  "parent": null
 },
 "provenance": {
  "renderer_version": 8,
  "representation_hash": "0df60237a8177e44fcfe07beafe1e784959eb707741da3e5a0c233ba058a5471",
  "retrieved_at": "2026-07-30T18:17:57.344275+00:00",
  "source_revision": "a2fba06569b8c38bc6677ec5fa6470367167dad0",
  "xml_hash": "4dec82ba818016210b758a377dbcf8e4b31af2d21fae9d995169e6accad37fc1"
 },
 "ref_id": "forskrift/1993-04-30-318",
 "schema_version": "1",
 "slug": "forskrift-om-hva-som-er-dopingmidler",
 "source": {
  "dataset": "gjeldende-sentrale-forskrifter",
  "license": "NLOD 2.0",
  "license_url": "https://data.norge.no/nlod/no/2.0",
  "provider": "Lovdata",
  "statement": "Inneholder data under Norsk lisens for offentlige data (NLOD 2.0), tilgjengeliggjort av Lovdata. Informasjonen er transformert og strukturert av Lovspor og gjengis ikke i sin opprinnelige form."
 },
 "temporal": {
  "date_in_force": "1993-07-01",
  "last_change_in_force": "2025-03-14",
  "note": "Current corpus state; not an applicability-at-date determination.",
  "status": "current"
 },
 "text": "\n# Forskrift om hva som skal anses som dopingmidler\n\n## § 1.\n\nSom dopingmidler etter forskriften regnes\n\n1. stoffer som er oppført på særskilt liste (dopinglisten)\n2. salter av disse stoffer og mulige stereoisomere, estere og etere av stoffene og deres salter\n3. blandinger som inneholder stoffer nevnt i bokstav a og b.\n\nMed blandinger menes blandinger av enhver art i fast form, flytende form eller gassfase, oppløsninger, fortynninger, ekstrakter, konsentrater, farmasøytiske preparater og bearbeidede former av stoffene når bearbeidelsen ikke fører til en kjemisk endring av stoffene.\n\n> Endret ved [forskrift 24 mai 2013 nr. 518](forskrift/2013-05-24-518).\n\n## § 2.\n\nDirektoratet for medisinske produkter kan i vedlegg til forskriften fastsette og endre hvilke stoffer som regnes som dopingmidler, jf. reglene i [forvaltningsloven kapittel VII](lov/1967-02-10/kapvii).\n\n> Endret ved [forskrifter 21 des 2000 nr. 1372](forskrift/2000-12-21-1372) (i kraft 1 jan 2001), [24 mai 2013 nr. 518](forskrift/2013-05-24-518), [20 des 2023 nr. 2165](forskrift/2023-12-20-2165) (i kraft 1 jan 2024).\n\n## § 3.\n\nLegemidler med innhold av dopingmidler kan, til eget personlig, medisinsk bruk, medbringes ved inn- eller utreise når\n\n1. legemidlene er rekvirert av lege eller tannlege,\n2. den reisende kan dokumentere, for eksempel ved hjelp av pakningens etikett, resept eller legeerklæring, at legemidlene er rekvirert til eget personlig, medisinsk bruk, og\n3. mengden medbrakt legemiddel ikke overstiger 30 dagers forbruk i henhold til angitt dosering.\n\nTolletaten kan kreve at den reisende legger fram dokumentasjon etter denne bestemmelsen. Dokumentasjonen må fremlegges på tidspunktet for inn- eller utreise.\n\n> Endret ved forskrift [14 mars 2025 nr. 813](forskrift/2025-03-14-813).\n\n## Dopingliste\n\nFastsatt av Statens legemiddelverk med hjemmel i [forskrift 30. april 1993 nr. 318](forskrift/1993-04-30-318) om hva som skal anses som dopingmidler [§ 2](forskrift/1993-04-30-318/§2). Dopinglisten gjelder som en del av forskriften.\n\nSom dopingmidler regnes følgende stoffer og disse stoffers salter og mulige stereosiomere, estere, etere av stoffene og deres salter; jf. [forskriften § 1](forskrift/1993-04-30-318/§1) bokstav b:\n\n| *Stoffnavn* | *Kjemisk navn* | *CAS-nummer* |\n| --- | --- | --- |\n| adrafinil | (±)-2-benzhydrylsulfinyletanhydroksaminsyre | 63547-13-7 |\n| adrenalin, epinefrin | (R)-4-(1-hydroksy-2-(metylamino)etyl)benzen-1,2-diol | 51-43-4 |\n| amifenazol | 5-fenyl-1,3-thiazol-2,4-diamin | 490-55-1 |\n| androsteron | 3α-hydroksy-5α-androstan-17-on | 53-41-8 |\n| – | 5α-androstan-3α,17α-diol | 6165-21-5 |\n| hombreol | 5α-androstan-3α,17β-diol | 1852-53-5 |\n| – | 5α-androstan-3β,17α-diol; 3β,17α-dihydroksy-5α-androstan | – |\n| 3β-androstandiol | 5α-androstan-3β,17β-diol | 571-20-0 |\n| androstendiol, 5-androstendiol | androst-5-en-3β,17β-diol | 521-17-5 |\n| – | androst-4-en-3α,17α-diol | – |\n| – | androst-4-en-3α,17β-diol; 4-androsten-3α,17β-diol | 1852-61-5 |\n| – | androst-4-en-3β,17α-diol | – |\n| – | androst-5-en-3α,17α-diol | 47122-33-8 |\n| – | androst-5-en-3α,17β-diol | – |\n| – | androst-5-en-3β,17α-diol; androst-5-en-3,17-diol, (3β,17α)- | 1963-03-7 |\n| 1-androstendiol | 5α-androst-1-en-3β,17β-diol | 5323-27-3 |\n| 4-androstendiol | androst-4-en-3β,17β-diol | 1156-92-9 |\n| androstendion, 4-androstendion | androst-4-en-3,17-dion | 63-05-8 |\n| 1-androstendion | 5α-androst-1-en-3,17-dion | 571-40-4 |\n| 5-androstendion | androst-5-en-3,17-dion | 571-36-8 |\n| bitolterol | (RS)-[4-(1-hydroksy-2-tert-butylamino-etyl)-2-(4-metylbenzoyl)oxy-fenyl] 4-metylbenzoat | 30392-40-6 |\n| bolandiol | 19-norandrostendiol; 19-nor-4-androstendiol; estr-4-en-3β,17β-diol; 3β-dihydronandrolon | 19793-20-5 |\n| bolasteron | 7α,17α-dimetyltestosteron | 1605-89-6 |\n| boldenon, 1-dehydrotestosteron | androsta-1,4-dien-17β-ol-3-on | 846-48-0 |\n| boldion, androstadiendion, 1-dehydroandrostendion | androsta-1,4-dien-3,17-dion; 1,4-androstadien-3,17-dion | 897-06-3 |\n| bromantan, bromontan, adamantylbromfenylamin | N-(4-bromofenyl)adamantan-2-amin | 87913-26-6 |\n| cyclazodon | (RS)-2-(syklopropylamino)-5-fenyl-1,3-oxazol-4-on | 14461-91-7 |\n| danazol | 17α-etynyl-17β-hydroksyandrost-4-eno[2,3-d]isoksazol | 17230-88-5 |\n| dehydroklormetyltestosteron, klorodehydrometyltestosteron | 4-klor-17β-hydroksy-17α-metylandrosta-1,4-dien-3-on | 2446-23-3 |\n| desoksymetyltestosteron, DMT | 17α-metyl-5α-androst-2-en-17β-ol | 3275-64-7 |\n| DHEA (dehydroepiandrosteron, prosteron), androstenolon | androst-5-en-3β-ol-17-on; 3β-hydroksyandrost-5-en-17-on | 53-43-0 |\n| dihydrotestosteron, DHT, 5α-dihydrotestosteron, 5α-DHT, androstanolon, stanolon | 17β-hydroksy-5α-androstan-3-on; 5α-androstan-17β-ol-3-on | 521-18-6 |\n| dobutamin | (RS)-4-(2-{[4-(4-hydroksyfenyl)butan-2-yl]amino}etyl)benzen-1,2-diol | 34368-04-2 |\n| doksapram | 1-etyl-4-(2-morfolin-4-yletyl)-3,3-difenyl-pyrrolidin-2-on | 309-29-5 |\n| dopamin, DA | 3,4-dihydroksyfenetylamin | 51-61-6 |\n| drostanolon, dromostanolon | 2α-metyl-4,5α-dihydrotestosteron; 2α-metyl-5α-androstan-17β-ol-3-on | 58-19-5 |\n| efedrin | rel-(R,S)-2-(metylamino)-1-fenylpropan-1-ol | 299-42-3 |\n| epiandrosteron, isoandrosteron | 3β-hydroksy-5α-androstan-17-on; 3β-androsteron; 5α-androstan-3β-ol-17-on | 481-29-8 |\n| epi-dihydrotestosteron, 17-epi-dihydrotestosteron | 17α-hydroksy-5α-androstan-3-on | 571-24-4 |\n| erytropoietin (EPO), erytropoetin, hematopoietin, hemopoietin |  |  |\n| etafedrin, etylefedrin | (1R,2S)-2-[etyl(metyl)amino]-1-fenyl-1-propanol | 48141-64-6 |\n| etamivan | N,N-dietyl-4-hydroksy-3-metoksybenzamid | 304-84-7 |\n| etilefrin | (2-etylamino-1-(3'-hydroksy-fenyl)etanol; (RS)-3-[2-(etylamino)-1-hydroksyetyl]fenol | 709-55-7 |\n| etyløstrenol, etylnandrol | 19-nor-17α-pregn-4-en-17-ol | 965-90-2 |\n| famprofazon | 1-metyl-5-{[metyl(1-fenylpropan-2-yl)amino]metyl}-2-fenyl-4-(propan-2-yl)-1,2-dihydro-3H-pyrazol-3-on | 22881-35-2 |\n| fenbutrazat | 2-(3-metyl-2-fenylmorfolin-4-yl)etyl 2-fenylbutanoat | 4378-36-3 |\n| fenkamin | 1,3,7-trimetyl-8-({2-[metyl(1-fenylpropan-2-yl)amino]etyl}amino)-3,7-dihydro-1H-purin-2,6-dion | 28947-50-4 |\n| fenoterol | (RR,SS)-5-(1-hydroksy-2-{[2-(4-hydroksyfenyl)-1-metyletyl]amino}etyl)benzen-1,3-diol | 130156-24-0 |\n| fenprometamin | N-metyl-2-fenylpropan-1-amin | 93-88-9 |\n| fenylpropanolamin, PPA | (1R,2S)-2-amino-1-fenylpropan-1-ol | 14838-15-4 |\n| fluoksymesteron, androfluoren | 9α-fluor-11β-hydroksy-17α-metyltestosteron; 9α-fluor-17α-metylandrost-4-en-11β,17β-diol-3-on | 76-43-7 |\n| formebolon, formyldienolon | 2-formyl-11α-hydroksy-17α-metyl-δ1-testosteron | 2454-11-7 |\n| furazabol, androfurazanol | 17α-metyl-5α-androsta[2,3-c]furazan-17β-ol | 1239-29-8 |\n| furfenoreks | furfurylmetylamfetamin | 3776-93-0 |\n| gestrinon, etylnorgestrienon | 17α-etynyl-18-metylestra-4,9,11-trien-17β-ol-3-on | 16320-04-0 |\n| gonadotropiner (LH, hCG) |  |  |\n| heptaminol | (RS)-6-amino-2-metylheptan-2-ol | 372-66-7 |\n| 4-hydroksytestosteron, 4-OHT | 4,17β-dihydroksyandrost-4-en-3-on | 2141-17-5 |\n| isomethepten | N,6-dimetylhept-5-en-2-amin | 503-01-5 |\n| isoprenalin, isoproterenol | (RS)-4-[1-hydroksy-2-(isopropylamino)etyl]benzen-1,2-diol | 7683-59-2 |\n| kalusteron | 7β,17α-dimetyltestosteron | 17021-26-0 |\n| karfedon, fenylpiracetam, fonturacetam | (R,S)-2-(2-okso-4-fenylpyrrolidin-1-yl)acetamid | 77472-70-9 |\n| klenbuterol | (RS)-1-(4-amino-3,5-diklorfenyl)-2-(tert-butylamino)etan-1-ol | 37148-27-9 |\n| klorprenalin | 1-(2-klorfenyl)-2-(propan-2-ylamino)etanol | 3811-25-4 |\n| klostebol, 4-klortestosteron, klorotestosteron | 4-klorandrost-4-en-17β-ol-3-on | 1093-58-9 |\n| kropropamid | 2-[[(E)-but-2-enoyl]-propylamino]-N,N-dimetylbutanamid | 633-47-6 |\n| krotetamid | 2-[[(E)-but-2-enoyl]-etylamino]-N,N-dimetylbutanamid | 6168-76-9 |\n| kvinbolon | 1-dehydrotestosteron 17β-cyclopent-1-enyl eter | 2487-63-0 |\n| LGD-4033, ligandrol | 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroksyetyl]pyrrolidin-1-yl]-2-(trifluorometyl)benzonitril | 1165910-22-4 |\n| mekano vekstfaktorer (MGFs) |  |  |\n| meklofenoksat, sentrofenoksin | 2-dimetylaminoetyl (4-klorfenoksy)acetat | 51-68-3 |\n| mestanolon, metylandrostanolon | 17α-metyl-4,5α-dihydrotestosteron | 521-11-9 |\n| mesterolon | 1α-metyl-4,5α-dihydrotestosteron | 1424-00-6 |\n| metandienon, metandrostenolon | 17β-hydroksy-17α-metylandrosta-1,4-dien-3-on; 17α-metylandrost-1,4-dien-17β-ol-3-on | 72-63-9 |\n| metandriol, metylandrostendiol, metyl-5-androstendiol | 17α-metylandrost-5-en-3β,17β-diol | 521-10-8 |\n| metaraminol, metaradrin | (1R,2S)-3-[-2-amino-1-hydroksy-propyl]fenol | 54-49-9 |\n| metasteron, metyldrostanolon | 2α,17α-dimetyl-4,5α-dihydrotestosteron | 3381-88-2 |\n| metenolon, metylandrostenolon | 1-metyl-5α-androst-1-en-17β-ol-3-on | 153-00-4 |\n| metoksyfenamin, 2-metoksy-N-metylamfetamin | 1-(2-metoksyfenyl)-N-metylpropan-2-amin | 93-30-1 |\n| metyldienolon | 17α-metyl-19-nor-δ9-testosteron; 17α-metylestra-4,9-dien-17β-ol-3-on | 14531-89-6 |\n| metylefedrin, N-metylefedrin | (1R,2S)-2-(dimetylamino)-1-fenyl-1-propanol | 552-79-4 |\n| metylnortestosteron, 11β-metyl-19-nortestosteron, 11β-MNT | 11β-metylestr-4-en-17β-ol-3-on | 18046-77-0 |\n| metyltestosteron, 17α-metyltestosteron | 17α-metylandrost-4-en-17β-ol-3-on | 58-18-4 |\n| metyl-1-testosteron, 17α-metyl-1-testosteron, M1T, metyldihydroboldenon | 17β-hydroksy-17α-metyl-5α-androst-1-en-3-on; 17α-metyl-5α-androst-1-en-17β-ol-3-on | 65-04-3 |\n| metyltrienolon, metribolon | 17α-metylestra-4,9,11-trien-17β-ol-3-on | 965-93-5 |\n| miboleron, dimetylnortestosteron, DMNT | 7α,17α-dimetyl-19-nortestosteron | 3704-09-4 |\n| nandrolon, 19-nortestosteron | estr-4-en-17β-ol-3-on; 19-norandrost-4-en-17β-ol-3-on | 434-22-0 |\n| niketamid, nikotinsyre dietylamid | N,N-dietyl-3-pyridinkarboksamid | 59-26-7 |\n| noradrenalin (NA), norepinefrin (NE) | (R)-4-(2-amino-1-hydroksyetyl)benzen-1,2-diol | 51-41-2 |\n| 19-norandrostendion, bolandion | estr-4-en-3,17-dion; 19-norandrost-4-en-3,17-dion | 734-32-7 |\n| 19-norandrosteron | 5α-estran-3α-ol-17-on; 3α-hydroksy-5α-estran-17-on | 1225-01-0 |\n| norboleton | 17α-etyl-18-metyl-19-nortestosteron | 1235-15-0 |\n| noretandrolon, 3-ketoetylestrenol, etylestrenolon | 17α-etyl-19-nortestosteron | 52-78-8 |\n| 19-noretiokolanolon | 5β-estran-3α-ol-17-on | 33036-33-8 |\n| norklostebol | 4-klorestr-4-en-17β-ol-3-on | 13583-21-6 |\n| oksabolon | 4-hydroksy-19-nortestosteron | 4721-69-1 |\n| oksandrolon | 17α-metyl-2-oksa-4,5α-dihydrotestosteron | 53-39-4 |\n| oksilofrin, metylsynefrin, hydroksyefrin, oksyefrin, 4-HMP | (1S\\*,2R\\*)-(±)-4-(1-hydroksy-2-metylamino-propyl)fenol | 365-26-4 |\n| oksymesteron, metandrostendiolon | 4-hydroksy-17α-metyltestosteron; 17α-metylandrost-4-en-4,17β-diol-3-on | 145-12-0 |\n| oksymetolon | 2-hydroksymetylen-17α-metyl-4,5α-dihydrotestosteron | 434-07-1 |\n| oktopamin, para-oktopamin | para-hydroksy-fenyl-etanolamin;<br>(RS)-4-(2-amino-1-hydroksy-etyl)fenol | 104-14-3 |\n| orciprenalin, metaproterenol | (RS)-5-[1-hydroksy-2-(isopropylamino)etyl]benzen-1,3-diol | 586-06-1 |\n| ortetamin, 2-metylamfetamin | (±)-1-(2-metylfenyl)propan-2-amin | 5580-32-5 |\n| ostarin, enobosarm, MK-2866 | ((2S)-3-(4-cyanofenoksy)-N-[4-cyano-3-(trifluorometyl)fenyl]-2-hydroksy-2-metylpropanamid | 841205-47-8 |\n| pentetrazol, pentylentetrazol, metrazol, pentametylentetrazol | 6,7,8,9-tetrahydro-5H-tetrazolo(1,5-a)azepin | 54-95-5 |\n| prasteron (dehydroepiandrosteron, DHEA) | androst-5-en-3β-ol-17-on; 3β-hydroksyandrost-5-en-17-on | 53-43-0 |\n| prenalterol | 4-{[(2S)-2-hydroksy-3-(isopropylamino)propyl]oxy}fenol | 57526-81-5 |\n| prolintan | 1-(1-fenylpentan-2-yl)pyrrolidin | 493-92-5 |\n| propylheksedrin, heksahydro-metamfetamin | (±)-1-sykloheksyl-N-metylpropan-2-amin | 101-40-6 |\n| prostanozol, demetylstanozolol tetrahydropyran eter | 17α-demetylstanozolol 17β-tetrahydropyran eter | 1186001-41-1 |\n| RAD140, testolon | 2-klor-4-{[(1R,2S)-1-[5-(4-cyanofenyl)-1,3,4-oxadiazol-2-yl]-2-hydroksypropyl]amino}-3-metylbenzonitril | 1182367-47-0 |\n| rimiterol | 4-{(S)-hydroksy[(2R)-piperidin-2-yl]metyl}benzen-1,2-diol | 32953-89-2 |\n| sibutramin | 1-(1-(4-klorfenyl)syklobutyl)-N,N,2,2-tetrametylpropan-1-amin | 106650-56-0 |\n| somatropin/hGh, hGH, HGH, GH |  |  |\n| stanozolol, androstanazol, stanazol | 17α-metyl-2'H-5α-androst-2-eno[3,2-c]pyrazol-17β-ol | 10418-03-8 |\n| stenbolon | 2-metyl-5α-androst-1-en-17β-ol-3-on | 5197-58-0 |\n| stryknin | stryknidin-10-on | 57-24-9 |\n| testosteron | 17β-hydroksyandrost-4-en-3-on; androst-4-en-17β-ol-3-on | 58-22-0 |\n| 1-testosteron, δ1-dihydrotestosteron, dihydroboldenon | 17β-hydroksy-5α-androst-1-en-3-on | 65-06-5 |\n| tetrahydrogestrinon, THG | 18a-homo-pregna-4,9,11-trien-17β-ol-3-on; 17α-etyl-18-metylestra-4,9,11-trien-17β-ol-3-on | 618903-56-3 |\n| tibolon | 7α-metyl-19-nor-17α-pregn-5(10)-en-20-yn-17-ol-3-on | 5630-53-5 |\n| trenbolon, trienolon, trienbolon | estra-4,9,11-trien-17β-ol-3-on | 10161-33-8 |\n| vekstfaktorer – insulinlignende (eks. IGF-1), somatomedin C |  |  |\n| veksthormon/hGh, somatotropin |  |  |\n| zeranol, α-zeralanol, zeralanol | (3S,7R)-7,14,16-trihydroksy-3-metyl-3,4,5,6,7,8,9,10,11,12-dekahydro-1H-2-benzoksasyclotetradekin-1-on | 26538-44-3 |\n| zilpaterol | (±)-trans-4,5,6,7-tetrahydro-7-hydroksy-6-(isopropylamino)-imidazo[4,5,1-jk]-[1]benzazepin-2(1H)-on | 119520-05-7 |\n\n> Endret ved [forskrifter 30 sep 1994 nr. 911](forskrift/1994-09-30-911), [17 nov 1994 nr. 1055](forskrift/1994-11-17-1055), [28 des 2000 nr. 1693](forskrift/2000-12-28-1693), [12 sep 2006 nr. 1064](forskrift/2006-09-12-1064) (i kraft 1 okt 2006), [11 okt 2022 nr. 1728](forskrift/2022-10-11-1728), [11 okt 2022 nr. 1781](forskrift/2022-10-11-1781), [25 jan 2023 nr. 90](forskrift/2023-01-25-90).\n",
 "title": "Forskrift om hva som skal anses som dopingmidler",
 "type": "forskrift"
}